Phaseline

Targets › C5AR1

C5AR1 (C5a anaphylatoxin chemotactic receptor 1): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Immunology; next expected readout Jul 2027.

Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a, stimulating chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase. (UniProt, P21730)

Open in Phaseline: the race on C5AR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AmgenAvacopan
C5a anaphylatoxin chemotactic receptor antagonist
C5AR1Phase 4Antineutrophil Cytoplasmic Antibody-associated Vasculitis; Vasculitis; ANCA Associated Vasculitis (AAV); Granulomatosis With PolyangiitisJul 2027

Conditions

Antineutrophil Cytoplasmic Antibody-associated Vasculitis (1) Vasculitis (1) ANCA Associated Vasculitis (AAV) (1) Granulomatosis With Polyangiitis (1)

Modalities

small molecule (1)

Companies

Amgen (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.